Identification of biomarkers and their functions in dasatinib‑resistant pancreatic cancer using bioinformatics analysis

Wei,Jingsun; Han,Rongbo; Su,Xinyu; Chen,Yuetong; Shi,Junfeng; Cui,Xiaowen; Zhang,Honghong; Gong,Yang; Chu,Xia; Chen,Jinfei

doi:10.3892/ol.2019.10281

Identification of biomarkers and their functions in dasatinib‑resistant pancreatic cancer using bioinformatics analysis

Authors:
- Jingsun Wei
- Rongbo Han
- Xinyu Su
- Yuetong Chen
- Junfeng Shi
- Xiaowen Cui
- Honghong Zhang
- Yang Gong
- Xia Chu
- Jinfei Chen
View Affiliations

Affiliations: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China, Department of Oncology, Nanjing First Hospital, Southeast University, Nanjing, Jiangsu 210006, P.R. China
Published online on: April 25, 2019 https://doi.org/10.3892/ol.2019.10281
Pages: 197-206
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dasatinib is a tyrosine kinase inhibitor, which inhibits tumor proliferation by blocking SRC pathways and is considered as a potential treatment of various epithelial neoplasms, including pancreatic cancer. However, dasatinib efficacy is largely limited due to drug resistance. In the present study, bioinformatics strategies were used to investigate the potential mechanisms of dasatinib‑resistance in pancreatic cancer. The gene expression profiles of the Panc0403, Panc0504, Panc1005 (dasatinib‑sensitive), SU8686, MiaPaCa2 and Panc1 (acquired dasatinib‑resistant) cell lines were obtained from the gene expression omnibus database. The differentially expressed genes (DEGs) were then selected using R software. In addition, gene ontology (GO) and pathway enrichment analysis were performed through the Database for Annotation, Visualization and Integrated Discovery. A protein‑protein interaction (PPI) network was constructed and analyzed to determine the hub genes using the Search Tool for the Retrieval of Interacting Genes database. A total of 472 DEGs, including vimentin, transmembrane 4 l six family member 18 and S100 calcium binding protein P, were identified. Enrichment analysis by GO function demonstrated that DEGs were associated with extracellular components, signal regulation and binding factors. The analysis of the Kyoto Encyclopedia of Genes and Genomes demonstrated that several adenocarcinoma pathways were enriched, including the phosphoinositide 3‑kinases/protein kinase B and mitogen‑activated protein kinase signaling pathways. Some hub genes were highlighted following the PPI network construction, including Rac family small GTPase 1, laminin subunit α3, integrin subunit β4, integrin subunit α2, collagen type VI α1 chain, collagen type I α2 chain, arrestin β1 and synaptotagmin 1, which may be associated with pancreatic adenocarcinoma prognosis. A total of five out of eight hub genes were highly associated with the overall survival rate (P<0.05). In conclusion, the present study reported novel insights into the mechanisms of dasatinib resistance. Identification of these hub genes may be considered as potential novel treatment targets for dasatinib‑resistance in pancreatic cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lau MK, Davila JA and Shaib YH: Incidence and survival of pancreatic head and body and tail cancers: A population-based study in the United States. Pancreas. 39:458–462. 2010. View Article : Google Scholar : PubMed/NCBI
4	Quaresma M, Coleman MP and Rachet B: 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: A population-based study. Lancet. 385:1206–1218. 2015. View Article : Google Scholar : PubMed/NCBI
5	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
6	Shah NP, Tran C, Lee FY, Chen P, Norris D and Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305:399–401. 2004. View Article : Google Scholar : PubMed/NCBI
7	Keating GM: Dasatinib: A review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia. Drugs. 77:85–96. 2017. View Article : Google Scholar : PubMed/NCBI
8	Summy JM and Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
9	Koon HK, Chan PS, Wong RN, Wu ZG, Lung ML, Chang CK and Mak NK: Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem. 108:1356–1363. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Wilson MJ, Slaton JW, Sinha AA, Ewing SL and Pei D: Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP). J Androl. 30:259–274. 2009. View Article : Google Scholar : PubMed/NCBI
11	Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA, Tan SZ, Tokatly I, Zaiden N, Poellinger L, et al: Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol. 9:889–905. 2015. View Article : Google Scholar : PubMed/NCBI
12	Gnoni A, Marech I, Silvestris N, Vacca A and Lorusso V: Dasatinib: An anti-tumour agent via Src inhibition. Curr Drug Targets. 12:563–578. 2011. View Article : Google Scholar : PubMed/NCBI
13	Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH and Gallick GE: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 168:962–972. 2006. View Article : Google Scholar : PubMed/NCBI
14	Nagaraj NS, Smith JJ, Revetta F, Washington MK and Merchant NB: Targeted inhibition of Src kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 9:2322–2332. 2010. View Article : Google Scholar : PubMed/NCBI
15	Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, et al: Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 139:292–303. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, Gieseler F and Ungefroren H: Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: Implications for in vivo mode of action. Mol Cancer. 14:1992015. View Article : Google Scholar : PubMed/NCBI
17	Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, Gieseler F and Ungefroren H: Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: Implications for in vivo mode of action. Mol Cancer. 14:1992015. View Article : Google Scholar : PubMed/NCBI
18	Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, et al: The mitogen-activated protein kinase pathway facilitates resistance to the src inhibitor dasatinib in thyroid cancer. Mol Cancer Ther. 15:1952–1963. 2016. View Article : Google Scholar : PubMed/NCBI
19	Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M and Hammerman PS: Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther. 13:475–482. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lilian A, Denis S, Johnston JB and Raquel A: p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res. 35:99–102. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhang L, Huang Y, Zhuo W, Zhu Y, Zhu B and Chen Z: Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer. Med Oncol. 34:892017. View Article : Google Scholar : PubMed/NCBI
22	Andrikou K, Peterle C, Pipitone S, Salati M and Cascinu S: Emerging antibodies for the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 22:39–51. 2017. View Article : Google Scholar : PubMed/NCBI
23	Knapinska AM, Estrada CA and Fields GB: The roles of matrix metalloproteinases in pancreatic cancer. Prog Mol Biol Transl Sci. 148:339–354. 2017. View Article : Google Scholar : PubMed/NCBI
24	Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, et al: A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 31:918–926. 2013. View Article : Google Scholar : PubMed/NCBI
25	Chen Z, Zhao L, Shi K and Chen B: Mechanism comparison of gemcitabine and dasatinib-resistant pancreatic cancer by integrating mRNA and miRNA expression profiles. Clin Lab. 64:749–757. 2018. View Article : Google Scholar : PubMed/NCBI
26	Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14:36292007. View Article : Google Scholar : PubMed/NCBI
27	Lazarova DL and Bordonaro M: Vimentin, colon cancer progression and resistance to butyrate and other HDAC is. J Cell Mol Med. 20:989–993. 2016. View Article : Google Scholar : PubMed/NCBI
28	Efferth T, Gebhart E, Ross DD and Sauerbrey A: Identification of gene expression profiles predicting tumor cell response to L-alanosine. Biochem Pharmacol. 66:613–621. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hustinx SR, Hruban RH, Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, Brown PN, Argani P, Ashfaq R, Fukushima N, et al: Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: A potential new target for therapy. Cancer Biol Ther. 4:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
30	Lopez J, Hesling C, Prudent J, Popgeorgiev N, Gadet R, Mikaelian I, Rimokh R, Gillet G and Gonzalo P: Src tyrosine kinase inhibits apoptosis through the Erk1\|[sol]\|2-dependent degradation of the death accelerator Bik. Cell Death Differ. 19:1459–1469. 2012. View Article : Google Scholar : PubMed/NCBI
31	Mithraprabhu S, Khong T and Spencer A: Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. Cell Death Dis. 5:e11342014. View Article : Google Scholar : PubMed/NCBI
32	Guerrero-Zotano A, Mayer IA and Arteaga CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016. View Article : Google Scholar : PubMed/NCBI
33	Guri Y and Hall MN: mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer. 2:688–697. 2016. View Article : Google Scholar : PubMed/NCBI
34	Xu Z, Mei J and Tan Y: Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt. Int J Oncol. 50:93–100. 2017. View Article : Google Scholar : PubMed/NCBI
35	Kim MH and Kim J: Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci. 74:1457–1474. 2017. View Article : Google Scholar : PubMed/NCBI
36	Xili Y, Yue L, Jianhua Z, Fei G, Dinghong M, Nianyun W, Guohui L and Guanghua G: Analysis of the mechanism of drug resistance of VIM-2-type metallo-β-lactamase-producing Acinetobacter baumannii isolated from burn patients and its homology. Zhonghua shao shang za zhi (Chinese). 31:205–210. 2015.
37	Miyamoto T, Kashima H, Yamada Y, Kobara H, Asaka R, Ando H, Higuchi S, Ida K, Mvunta DH and Shiozawa T: Lipocalin 2 enhances migration and resistance against cisplatin in endometrial carcinoma cells. PLoS One. 11:e01552202016. View Article : Google Scholar : PubMed/NCBI
38	Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, Friedrich T and Clarke RJ: Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 6:2126–2133. 2014. View Article : Google Scholar : PubMed/NCBI
39	Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, Sun K, Xiong H, Jiang G, Zhang B, et al: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer. 8:3752008. View Article : Google Scholar : PubMed/NCBI
40	Ersahin T, Tuncbag N and Cetin-Atalay R: The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954. 2015. View Article : Google Scholar : PubMed/NCBI
41	Xinling Z, Leina M, Jieqiong Q, Hui S, Wengong Y and Yuchao G: MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy. Mol Cell Biochem. 410:101–110. 2015. View Article : Google Scholar : PubMed/NCBI
42	Shenoy SK and Lefkowitz RJ: β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci. 32:521–533. 2011. View Article : Google Scholar : PubMed/NCBI
43	Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG and Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar : PubMed/NCBI
44	Pérez-Sancho J, Vanneste S, Lee E, McFarlane HE, Esteban Del Valle A, Valpuesta V, Friml J, Botella MA and Rosado A: The Arabidopsis synaptotagmin1 is enriched in endoplasmic reticulum-plasma membrane contact sites and confers cellular resistance to mechanical stresses. Plant Physiol. 168:132–143. 2015. View Article : Google Scholar : PubMed/NCBI
45	Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F and Charest A: The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res. 72:3764–3774. 2012. View Article : Google Scholar : PubMed/NCBI
46	Januchowski R, Świerczewska M, Sterzyńska K, Wojtowicz K, Nowicki M and Zabel M: Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. 7:1295–1310. 2016. View Article : Google Scholar : PubMed/NCBI
47	Zhu YP, Wan FN, Shen YJ, Wang HK, Zhang GM and Ye DW: Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth. Oncotarget. 6:14488–14496. 2015. View Article : Google Scholar : PubMed/NCBI
48	Kawakami K, Fujita Y, Kato T, Mizutani K, Kameyama K, Tsumoto H, Miura Y, Deguchi T and Ito M: Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. Int J Oncol. 47:384–390. 2015. View Article : Google Scholar : PubMed/NCBI
49	Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P, et al: Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 135:1110–1118. 2014. View Article : Google Scholar : PubMed/NCBI
50	Zhou G, Peng F, Zhong Y, Chen Y, Tang M and Li D: Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells. Int J Oncol. 50:933–941. 2017. View Article : Google Scholar : PubMed/NCBI
51	Pan Y, Wang N, Xia P, Wang E, Guo Q and Ye Z: Inhibition of Rac1 ameliorates neuronal oxidative stress damage via reducing Bcl-2/Rac1 complex formation in mitochondria through PI3K/Akt/mTOR pathway. Exp Neurol. 300:149–166. 2018. View Article : Google Scholar : PubMed/NCBI
52	Zhang T and Wang N: miR-135a confers resistance to gefitinib in non-small cell lung cancer cells by upregulation of RAC1. Oncol Res. 26:1191–1200. 2018. View Article : Google Scholar : PubMed/NCBI
53	Wang JY, Yu P, Chen S, Xing H, Chen Y, Wang M, Tang K, Tian Z, Rao Q and Wang J: Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction. Mol Oncol. 7:907–916. 2013. View Article : Google Scholar : PubMed/NCBI
54	Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, et al: The RAC1 P29S hotspot mutation in melanoma confers resistance to Pharmacological inhibition of RAF. Cancer Res. 74:48452014. View Article : Google Scholar : PubMed/NCBI